Expression of prognostic factors (EGFR, ER) by immunohistochemical staining method in male breast cancer.
Twelve male patients with operable breast cancer were evaluated for the expression of prognostic factors by immunohistochemical staining assay. Seven patients were stage I & II, and five patients were stage III. Axillary lymph node positivity was 42%. Nine patients were nuclear grade I, three were nuclear grade II, and none were nuclear grade III. The expression rate of EGFR (epidermal growth factor receptor), ER (estrogen receptor) were 8.3%, 70.0% respectively. This limited data suggest better tumor behavior in male than in female breast cancer. Adjuvant treatment should be considered in male breast cancer just as in females, based on axillary lymph node and ER states.
Chung
H C
HC
Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
Kim
D L
DL
Koh
E H
EH
Kim
J H
JH
Roh
J K
JK
Min
J S
JS
Lee
K S
KS
Yang
W I
WI
Kim
B S
BS
Lee
K B
KB
D001943:Breast Neoplasms / Q000737:chemistry* / Q000473:pathology; D002277:Carcinoma / Q000737:chemistry* / Q000473:pathology; D066246:ErbB Receptors / Q000032:analysis*; D006801:Humans; D007150:Immunohistochemistry; D008207:Lymphatic Metastasis; D008297:Male; D009367:Neoplasm Staging; D011379:Prognosis; D011960:Receptors, Estrogen / Q000032:analysis*
D011960:Receptors, Estrogen; D066246:ErbB Receptors